Latest Healthcare News

Visionflex Group reported an 8% increase in Annual Recurring Revenue to $1.6 million in Q2 FY25 despite an 11% revenue decline, securing key contracts with Spark Health, BUPA, and Indigenous Wellness Connect. The company targets EBITDA profitability by Q4 FY25 amid a maturing sales pipeline.

Visionflex Group Limited reported a net cash outflow from operations for the December 2024 quarter but secured significant financing, extending its funding runway to nearly 15 quarters.

Mach7 Technologies has initiated a A$5 million on-market share buy-back program, reflecting confidence in its robust financial health and growth outlook. The move underscores the company’s commitment to capital management amid reaffirmed FY25 revenue growth guidance.

Imagion Biosystems has secured a AU$3 million capital injection and resumed its collaboration with Siemens, setting the stage to prioritize FDA filings and advance its MagSense® HER2 breast cancer imaging program.

OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.

LTR Pharma reports compelling clinical results for its nasal spray ED treatment SPONTAN®, demonstrating rapid absorption and strong safety, alongside strategic partnerships and a robust $34 million cash position.

Doctor Care Anywhere delivered positive cash flow and revenue growth at the top of guidance in Q4 2024, while navigating a strategic shift with new leadership appointments and the closure of secondary care pathways.

Island Pharmaceuticals reports promising safety and anti-dengue activity in its Phase 2a trial of ISLA-101 and has commenced the Phase 2b therapeutic arm, backed by a fresh A$3.5 million capital raise.

MedAdvisor Limited reported a significant 38.6% drop in 2Q FY25 revenue due to vaccine program deferrals but expects a stronger second half driven by a diversified US pipeline and cost-saving initiatives.

Alcidion Group Limited reported robust Q2 FY25 sales of $13.1 million and improved cash flow, reinforcing its forecast to achieve EBITDA and cashflow positivity by the end of FY25.

Sigma Healthcare has achieved unanimous shareholder approval for its proposed merger with Chemist Warehouse, marking a pivotal step toward reshaping Australia's pharmaceutical retail landscape. The merger now awaits final court approval, with implementation anticipated in mid-February 2025.

Sigma Healthcare has successfully passed all key resolutions at its extraordinary general meeting, clearing a major hurdle for its proposed merger with Chemist Warehouse. The deal now awaits final court approval, with implementation expected in February.